Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. XOMA Corporation
  6. Summary
    XOMA   US98419J2069

XOMA CORPORATION

(XOMA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
18.07(c) 18.35(c) 17.87(c) 17.26(c) 17.17(c) Last
30 429 41 789 40 959 35 421 35 666 Volume
+1.18% +1.55% -2.62% -3.41% -0.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 20,8 M - -
Net income 2022 -3,51 M - -
Net Debt 2022 - - -
P/E ratio 2022 -46,0x
Yield 2022 -
Sales 2023 24,5 M - -
Net income 2023 0,40 M - -
Net Debt 2023 - - -
P/E ratio 2023 -143x
Yield 2023 -
Capitalization 196 M 196 M -
Capi. / Sales 2022 9,43x
Capi. / Sales 2023 8,01x
Nbr of Employees 12
Free-Float 94,7%
More Financials
Company
XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. It also acquires the economics associated with pre-commercial therapeutic candidates that are licensed... 
Read more
Sector
Biotechnology & Medical Research
Calendar
05/25 | 10:00amPresentation
More about the company
Ratings of XOMA Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about XOMA CORPORATION
05/19XOMA CORP : Change in Directors or Principal Officers, Submission of Matters to a Vote of ..
AQ
05/17XOMA to Present at H.C. Wainwright Global Investment Conference
AQ
05/05XOMA CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF O..
AQ
05/05XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05XOMA : Q1 Earnings Snapshot
AQ
05/05Earnings Flash (XOMA) XOMA CORPORATION Posts Q1 Revenue $3.1M
MT
05/05XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Eve..
AQ
04/14XOMA : 2022 Letter to Stockholders
PU
04/07NEXE Up 3.9% after Reporting Initial Order of XOMA Superfoods by Purity Life Health Pro..
MT
04/05XOMA CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/28NEXE Innovations Brings Coffee Product Lines to Amazon Prime; Up 2%
MT
03/24INSIDER SELL : Xoma
MT
03/21XOMA Declares Quarterly Preferred Stock Dividends
AQ
03/11XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference
AQ
03/10XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference
AQ
More news
News in other languages on XOMA CORPORATION
05/05XOMA Corporation annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/05Earnings Flash (XOMA) XOMA CORPORATION affiche un chiffre d'affaires de 3,1 millions de..
04/27Kuros kann Umsatz mit Medizinprodukten im ersten Quartal verdoppeln
04/07NEXE en hausse de 3,9 % après avoir annoncé une première commande de XOMA Superfoods pa..
03/28NEXE Innovations apporte des gammes de produits de café à Amazon Prime ; hausse de 2 %.
More news
Analyst Recommendations on XOMA CORPORATION
More recommendations
Chart XOMA CORPORATION
Duration : Period :
XOMA Corporation Technical Analysis Chart | XOMA | US98419J2069 | MarketScreener
Technical analysis trends XOMA CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 17,17 $
Average target price 62,50 $
Spread / Average Target 264%
EPS Revisions
Managers and Directors
James R. Neal Chairman & Chief Executive Officer
Thomas Burns Chief Financial Officer & Senior VP-Finance
W. Denman van Ness Lead Independent Director
Jack L. Wyszomierski Independent Director
Joseph M. Limber Independent Director
Sector and Competitors
1st jan.Capi. (M$)
XOMA CORPORATION-17.65%196
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-22.98%39 423
BIONTECH SE-40.00%37 588